Tirzepatide: Dual Incretin Agonism (GLP-1 + GIP) in Metabolic Research

### Why add GIP? Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted from intestinal K cells. Tirzepatide-class molecules co-activate **GLP-1R and GIPR**, allowing studies to test whether combined signaling improves insulin sensitivity, body weight trajectory, or lipid parameters beyond selective GLP-1 agonism—hypotheses evaluated in large outcome trials. ### Experimental distinctions Researchers comparing **GLP-1–selective** vs **dual incretin** agonists often report differences in: - **HbA1c** and fasting glucose in diabetes cohorts. - **Percent weight change** in obesity studies. - **Safety profiles** unique to dual targeting (trial-dependent). ### Laboratory alignment If your work involves metabolic peptides, pair literature review with analytical verification (HPLC/MS) and documented chain-of-custody for research vials. ### RUO Laboratory research use only. Not for human consumption. *Tirzepatide research-grade materials are listed in our peptide catalog for qualified buyers.*